Nanobac Pharmaceuticals Competitors

Acusphere (OTCMKTS:ACUS) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Acusphere and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Acusphere has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Earnings & Valuation

This table compares Acusphere and Nanobac Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Acusphere and Nanobac Pharmaceuticals, as reported by MarketBeat.

Summary

Nanobac Pharmaceuticals beats Acusphere on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares Affymax and Nanobac Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Affymax and Nanobac Pharmaceuticals, as reported by MarketBeat.

Profitability

This table compares Affymax and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Affymax has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Summary

Affymax beats Nanobac Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Nanobac Pharmaceuticals (OTCMKTS:NNBP) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

This table compares Nanobac Pharmaceuticals and ARYx Therapeutics' gross revenue, earnings per share and valuation.

Risk and Volatility

Nanobac Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Nanobac Pharmaceuticals and ARYx Therapeutics, as provided by MarketBeat.

Profitability

This table compares Nanobac Pharmaceuticals and ARYx Therapeutics' net margins, return on equity and return on assets.

Summary

Nanobac Pharmaceuticals beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

Nanobac Pharmaceuticals (OTCMKTS:NNBP) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Nanobac Pharmaceuticals and AtheroNova, as provided by MarketBeat.com.

Profitability

This table compares Nanobac Pharmaceuticals and AtheroNova's net margins, return on equity and return on assets.

Risk & Volatility

Nanobac Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its share price is 971% less volatile than the S&P 500.

Valuation & Earnings

This table compares Nanobac Pharmaceuticals and AtheroNova's gross revenue, earnings per share and valuation.

Summary

Nanobac Pharmaceuticals beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares China Botanic Pharmaceutical and Nanobac Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Risk & Volatility

China Botanic Pharmaceutical has a beta of 17.09, indicating that its share price is 1,609% more volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500.

Profitability

This table compares China Botanic Pharmaceutical and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for China Botanic Pharmaceutical and Nanobac Pharmaceuticals, as provided by MarketBeat.

Summary

China Botanic Pharmaceutical beats Nanobac Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and Nanobac Pharmaceuticals (OTCMKTS:NNBP) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares China Dongsheng International and Nanobac Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Risk and Volatility

China Dongsheng International has a beta of 13.38, indicating that its stock price is 1,238% more volatile than the S&P 500. Comparatively, Nanobac Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.

Profitability

This table compares China Dongsheng International and Nanobac Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for China Dongsheng International and Nanobac Pharmaceuticals, as provided by MarketBeat.com.

Summary

China Dongsheng International beats Nanobac Pharmaceuticals on 1 of the 1 factors compared between the two stocks.